275 filings
Page 6 of 14
8-K
kov2t kyb5a8
15 Feb 22
Regulation FD Disclosure
4:35pm
8-K
4q2da
14 Feb 22
Moleculin Provides Annamycin AML Program Update and Outlines Next Steps to Advance Towards Late-Stage Development
9:00am
8-K
3i1h0 8kc3c
18 Jan 22
Regulation FD Disclosure
8:30am
8-K
f3y6ym6u9zw3ohfqvb54
10 Jan 22
Regulation FD Disclosure
7:00am
8-K
5von 0vefc40
27 Dec 21
Entry into a Material Definitive Agreement
8:06am
8-K
bhdmayxrtf7jejqdy7h
17 Dec 21
Amendments to Articles of Incorporation or Bylaws
4:30pm
8-K
shhuz2zp368uqjcl93
1 Dec 21
Regulation FD Disclosure
8:30am
8-K
utm6nb cs
12 Nov 21
Moleculin Reports Third Quarter 2021 Financial Results and Provides Programs Update
7:30am
8-K
ntvcqt7pe
19 Oct 21
Regulation FD Disclosure
9:00am
8-K
0vorcwti722ohp0g2o17
18 Oct 21
Moleculin Announces Interim Data in Phase 1b/2 Clinical Trial of Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases
8:25am
8-K
wzylzkb1tsl9f
13 Sep 21
Regulation FD Disclosure
8:01am
8-K
qf8ynp
18 Aug 21
Regulation FD Disclosure
7:30am
8-K
g8e0dxxlcfqq9orn4w
12 Aug 21
Moleculin Reports Second Quarter 2021 Financial Results and Provides Programs Update
8:09am
8-K
3q8wy
13 Jul 21
Regulation FD Disclosure
8:35am
8-K
mpxqk6l
25 Jun 21
Entry into a Material Definitive Agreement
5:22pm
8-K
j4tfk3 eihl65a7k
21 Jun 21
Entry into a Material Definitive Agreement
4:17pm
8-K
5wxgt5
21 Jun 21
Moleculin Announces First Subject Enrolled and Dosed in Phase 1b/2 Clinical Trial of Annamycin for the Treatment of Sarcoma Lung Metastases
8:35am
8-K
i3pusg88em0liie87bjn
28 May 21
Submission of Matters to a Vote of Security Holders
4:34pm
8-K
ee0a36untatczig
25 May 21
Moleculin Commences Phase 1b/2 Clinical Trial of Annamycin for the Treatment of Sarcoma Lung Metastases
9:01am
8-K
er67gxem13cpenq0ng
19 May 21
Regulation FD Disclosure
5:08pm